|
SNRPB2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.25890000002293E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.90580000000362E-05 |
| Normal-vs-Stage2 |
9.9854999999982E-05 |
| Normal-vs-Stage3 |
6.07169999999879E-05 |
| Normal-vs-Stage4 |
3.27690000001546E-06 |
| Stage1-vs-Stage2 |
1.780380E-01 |
| Stage1-vs-Stage3 |
5.492000E-01 |
| Stage1-vs-Stage4 |
9.784400E-02 |
| Stage2-vs-Stage3 |
4.210200E-01 |
| Stage2-vs-Stage4 |
8.464800E-01 |
| Stage3-vs-Stage4 |
2.806800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.67330000000465E-06 |
| Normal-vs-AfricanAmerican |
6.857600E-03 |
| Normal-vs-Asian |
6.953700E-02 |
| Caucasian-vs-AfricanAmerican |
7.816400E-01 |
| Caucasian-vs-Asian |
7.301900E-02 |
| AfricanAmerican-vs-Asian |
3.314200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.77079999999597E-06 |
| Normal-vs-Female |
1.64953999999273E-05 |
| Male-vs-Female |
2.069800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
6.169400E-04 |
| Normal-vs-Age(41-60Yrs) |
1.52232999999224E-05 |
| Normal-vs-Age(61-80Yrs) |
2.73760000002454E-07 |
| Normal-vs-Age(81-100Yrs) |
1.940120E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.647000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.746300E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.833000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.526820E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.703200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.597900E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.759400E-01 |
| Classical-VS-Follicular |
2.767900E-02 |
| Classical-VS-Other |
9.630600E-01 |
| Classical-VS-Normal |
4.620700E-04 |
| Tall-VS-Follicular |
1.902620E-01 |
| Tall-VS-Other |
8.463000E-01 |
| Tall-VS-Normal |
3.938500E-03 |
| Follicular-VS-Other |
4.645400E-01 |
| Follicular-VS-Normal |
2.68189999996782E-06 |
| Other-VS-Normal |
1.481630E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.37599999949778E-07 |
| Normal-vs-N1 |
2.104600E-03 |
| N0-vs-N1 |
3.690400E-01 |
|
|
